Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 2, 2015BloodOpen Access

Eculizumab reduces complement activation, inflammation, endothelial damage, thrombosis, and renal injury markers in aHUS

View Full Paper
Ask AI
Bookmark
Share

Authors

RCRoxanne CofiellAKAnjli KukrejaKBKrystin Bedard

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Cofiell et al. (2015) studied this question.

synapsesocial.com/papers/6a7de2e72d182a3d7e99acafhttps://doi.org/10.1182/blood-2014-09-600411
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Platelet-associated complement factor H in healthy persons and patients with atypical HUS2009 · 79 citations
  2. 2TNF‐mediated inflammatory disease2007 · 2,101 citations
  3. 3How I treat: the clinical differentiation and initial treatment of adult patients with atypical hemolytic uremic syndrome2014 · 129 citations